Alysson Zanatta1, Ricardo Mendes Alves Pereira2, André Monteiro da Rocha3, Bruno Cogliati4, Edmund Chada Baracat5, Hugh S Taylor6, Eduardo Leme Alves da Motta7, Paulo Cesar Serafini5. 1. Department of Gynecology, São Paulo University School of Medicine, Sao Paulo, Brazil alysson.zanatta@gmail.com. 2. Endometriosis Center, Santa Joana Hospital, Sao Paulo, Brazil. 3. Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI. 4. Department of Molecular and Morphologic Sciences, São Paulo University School of Zootechny and Veterinary Medicine, Sao Paulo, Brazil. 5. Department of Gynecology, São Paulo University School of Medicine, Sao Paulo, Brazil. 6. Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA. 7. Department of Gynecology, São Paulo Federal University School of Medicine, Sao Paulo, Brazil.
Abstract
BACKGROUND: Very few studies have evaluated the expression of homeobox A10 (HOXA10) and steroid (estrogen and progesterone) receptors exclusively in deep endometriosis. Conclusions drawn from studies evaluating peritoneal and ovarian endometriosis are usually generalized to explain the pathogenesis of the disease as a whole. We aimed to evaluate the expression of HOXA10, estrogen receptor α (ER-α), progesterone receptor (PR), and PR-B in rectosigmoid endometriosis (RE), a typical model of deep disease. METHODS: We used RE samples from 18 consecutive patients to construct tissue microarray blocks. Nine patients each were operated during the proliferative and secretory phases of the menstrual cycle. We quantified the expressions of proteins by immunohistochemistry using the modified Allred score. RESULT: The HOXA10 was expressed in the stroma of nodules during the secretory phase in 5 of the 18 patients. Expression of ER-α (in 16 of 18 patients), PR (in 17 of 18 patients), and PR-B (17 of 18 patients) was moderate to strong in the glands and stroma of nodules during both phases. Expression of both PR (P = .023) and PR-B (P = .024) was significantly greater during the secretory phase. CONCLUSION: The HOXA10 is expressed in RE, where it likely imparts the de novo identity of endometriotic lesions. The ER-α, PR, and PR-B are strongly expressed in RE, which differs from previous studies investigating peritoneal and ovarian lesions. This suggests different routes of pathogenesis for each of the 3 types of endometriosis.
BACKGROUND: Very few studies have evaluated the expression of homeobox A10 (HOXA10) and steroid (estrogen and progesterone) receptors exclusively in deep endometriosis. Conclusions drawn from studies evaluating peritoneal and ovarian endometriosis are usually generalized to explain the pathogenesis of the disease as a whole. We aimed to evaluate the expression of HOXA10, estrogen receptor α (ER-α), progesterone receptor (PR), and PR-B in rectosigmoid endometriosis (RE), a typical model of deep disease. METHODS: We used RE samples from 18 consecutive patients to construct tissue microarray blocks. Nine patients each were operated during the proliferative and secretory phases of the menstrual cycle. We quantified the expressions of proteins by immunohistochemistry using the modified Allred score. RESULT: The HOXA10 was expressed in the stroma of nodules during the secretory phase in 5 of the 18 patients. Expression of ER-α (in 16 of 18 patients), PR (in 17 of 18 patients), and PR-B (17 of 18 patients) was moderate to strong in the glands and stroma of nodules during both phases. Expression of both PR (P = .023) and PR-B (P = .024) was significantly greater during the secretory phase. CONCLUSION: The HOXA10 is expressed in RE, where it likely imparts the de novo identity of endometriotic lesions. The ER-α, PR, and PR-B are strongly expressed in RE, which differs from previous studies investigating peritoneal and ovarian lesions. This suggests different routes of pathogenesis for each of the 3 types of endometriosis.
Authors: Katherine A Burns; Karina F Rodriguez; Sylvia C Hewitt; Kyathanahalli S Janardhan; Steven L Young; Kenneth S Korach Journal: Endocrinology Date: 2012-06-14 Impact factor: 4.736
Authors: Angelo Calcagno; Tiziana Grassi; Laura Mariuzzi; Stefania Marzinotto; Ambrogio P Londero; Maria Orsaria; Carlo Alberto Beltrami; Diego Marchesoni Journal: Hum Reprod Date: 2011-08-12 Impact factor: 6.918
Authors: Alysson Zanatta; André M Rocha; Filomena M Carvalho; Ricardo M A Pereira; Hugh S Taylor; Eduardo L A Motta; Edmund C Baracat; Paulo C Serafini Journal: J Assist Reprod Genet Date: 2010-09-07 Impact factor: 3.412
Authors: Paulo H M Bianchi; Ricardo M A Pereira; Alysson Zanatta; Jose Roberto Alegretti; Eduardo L A Motta; Paulo C Serafini Journal: J Minim Invasive Gynecol Date: 2009 Mar-Apr Impact factor: 4.137
Authors: Pietro G Signorile; Feliciano Baldi; Rossana Bussani; Mariarosaria D'Armiento; Maria De Falco; Alfonso Baldi Journal: J Exp Clin Cancer Res Date: 2009-04-09
Authors: Niraj R Joshi; Eduardo H Miyadahira; Yalda Afshar; Jae-Wook Jeong; Steven L Young; Bruce A Lessey; Paulo C Serafini; Asgerally T Fazleabas Journal: J Clin Endocrinol Metab Date: 2017-01-01 Impact factor: 5.958